VivoSeq
Ophthalmology

Anterior Uveitis

24

Pipeline Programs↗

4

Active Trials↗

15

Companies Involved↗

Anterior Uveitis is an emerging landscape with 24 programs across 15 companies. The most active players are Horizon Therapeutics Ireland DAC, Priovant Therapeutics, Inc., Eyegate Pharmaceuticals, Inc.. 6 therapies are approved with 9 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

49/100

Pipeline Velocity

15/100

Mech. Concentration

23/100

Completion Rate

85/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

H

Horizon Therapeutics Ireland DAC

1 program

Phase 1P

Priovant Therapeutics, Inc.

1 program

Phase 2E

Eyegate Pharmaceuticals, Inc.

1 program

Phase 2A

Aldeyra Therapeutics, Inc.

1 program

Phase 2Roche logo

Roche

1 program

Phase 2V

VivaVision Biotech, Inc

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

93%

Small molecule

26 of 28 classified programs — the dominant modality here.

7%ALL OTHERSMonoclonal antibody27%

Small molecule leads; the ring shows all 28 classified programs, each share of the total. Modality classified for 100% of 29 pipeline programs.

Analysis

Trial Status

20

clinical trials

Completed11 · 55%
Unknown status3 · 15%
Not yet recruiting3 · 15%
Terminated2 · 10%
Active, not recruiting1 · 5%

Clinical Trials

Trial Activity

20 trials

A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
Active, not recruiting·PPriovant Therapeutics, Inc.·Phase 3·NCT06431373·371 enrolled
Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis
Not yet recruiting·CCARE ARTHRITIS LTD.·Phase 4·NCT07018206·200 enrolled
Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis
Not yet recruiting·UUniversity Hospital, Rouen·Phase 3·NCT05651880·33 enrolled
A Phase 3 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis
Not yet recruiting·VVivaVision Biotech, Inc·Phase 3·NCT07136805·152 enrolled
A Phase 2 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis
Completed·VVivaVision Biotech, Inc·Phase 2·NCT06679153·89 enrolled
Proof of Concept Study to Evaluate Safety and Efficacy of LME636 in the Treatment of Acute Anterior Uveitis
Completed·AAlcon Research·Phase 2·NCT02482129·45 enrolled
A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis
Completed·PPriovant Therapeutics, Inc.·Phase 2·NCT05523765·26 enrolled
Exploratory Study on Topical ESBA105 in Acute Anterior Uveitis
Completed·EESBATech AG·Phase 2·NCT00823173·9 enrolled
Topical 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis
Completed·SSingapore National Eye Centre·Phase 4·NCT02943057·25 enrolled
Safety and Efficacy of Difluprednate 0.05% for the Treatment of Anterior Uveitis
Completed·AAlcon Research·Phase 3·NCT01201798·111 enrolled
Topical Administration of 0.15% Ganciclovir Gel for CMV Anterior Uveitis / Endotheliitis
Completed·SSingapore National Eye Centre·N/A·NCT01647529·29 enrolled
A Trial of the Efficacy and Safety of Izokibep in the Treatment of Non-anterior Uveitis
Completed·AACELYRIN Inc.·Phase 2·NCT04706741·7 enrolled
Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Anterior Uveitis
Completed·EEyegate Pharmaceuticals, Inc.·Phase 2·NCT00694135·40 enrolled
A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis
Completed·AAldeyra Therapeutics, Inc.·Phase 2·NCT02406209·45 enrolled
Safety and Efficacy Study of DSP-Visulex for the Treatment of Anterior Uveitis
Completed·AAciont Inc·Phase 1/2·NCT02309385·44 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)